Evaluation
*
*

Thinking about the impact of this session on your patients, please offer an estimate of the:

*
%
*
/month
*
1 (Disagree)2345 (Agree)
Identify key molecular attributes that have relevance in risk-adapted treatment of rare lymphomas, including Hodgkin lymphoma, mantle cell lymphomas, and marginal zone lymphomas
Determine which prognostic factors are clinically relevant in the era of novel agents for the treatment of chronic lymphocytic leukemia
Evaluate toxicity profiles and the best management of side effects associated with therapies used to treat rare lymphomas and leukemias
Discuss the role of the advanced practitioner in oncology in managing patients with these malignancies
*
1 (Low)2345 (High)
Ann McNeill, RN, MSN, APN
Sandra Kurtin, PhDc, ANP-C, AOCN
*
*